BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut 2019;68:977-84. [PMID: 30420398 DOI: 10.1136/gutjnl-2018-317021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Mak JWY, Yuen NTK, Yip TCF, Lam RHM, Lam BKH, Cheng CTY, Wong GLH, Chan FKL, Ng SC. No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. J Gastroenterol Hepatol 2022. [PMID: 35338526 DOI: 10.1111/jgh.15838] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Magro F, Alves C, Santiago M, Ministro P, Lago P, Correia L, Gonçalves R, Carvalho D, Portela F, Dias CC, Dignass A, Danese S, Peyrin-Biroulet L, Estevinho MM, Moreira P; on behalf GEDII (Portuguese IBD Group). Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis. United European Gastroenterol J 2021. [PMID: 34907660 DOI: 10.1002/ueg2.12183] [Reference Citation Analysis]
3 Shaffer SR, Rubin DT. Response to Tetangco and Hanauer. Am J Gastroenterol 2021;116:1959-60. [PMID: 34101668 DOI: 10.14309/ajg.0000000000001330] [Reference Citation Analysis]
4 Veyrard P, Nancey S, Roblin X. Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Aliment Pharmacol Ther 2021;54:843-4. [PMID: 34425008 DOI: 10.1111/apt.16541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 148] [Cited by in F6Publishing: 125] [Article Influence: 148.0] [Reference Citation Analysis]
7 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1089-100. [PMID: 33181088 DOI: 10.1016/S2468-1253(20)30298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
10 Balram B, Joshi H, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Baumgart DC, Peerani F. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Dig Dis Sci 2021;66:3985-92. [PMID: 33184796 DOI: 10.1007/s10620-020-06704-6] [Reference Citation Analysis]
11 Frias Gomes C, Chapman TP, Satsangi J. De-escalation of medical therapy in inflammatory bowel disease. Curr Opin Pharmacol 2020;55:73-81. [PMID: 33160250 DOI: 10.1016/j.coph.2020.09.014] [Reference Citation Analysis]
12 Rabbenou W, Ullman TA. Risk of Colon Cancer and Recommended Surveillance Strategies in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:791-807. [PMID: 33121696 DOI: 10.1016/j.gtc.2020.08.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
13 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020;52:481-91. [PMID: 32573825 DOI: 10.1111/apt.15876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Mizuno S, Ono K, Mikami Y, Naganuma M, Fukuda T, Minami K, Masaoka T, Terada S, Yoshida T, Saigusa K, Hirahara N, Miyata H, Suda W, Hattori M, Kanai T. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res 2020;18:69-78. [PMID: 32013315 DOI: 10.5217/ir.2019.00084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zhang W, Chen Y, Jiang H, Yang J, Wang Q, Du Y, Xu H. Integrated strategy for accurately screening biomarkers based on metabolomics coupled with network pharmacology. Talanta 2020;211:120710. [PMID: 32070601 DOI: 10.1016/j.talanta.2020.120710] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
17 Geneviève LD, Martani A, Mallet MC, Wangmo T, Elger BS. Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review. PLoS One 2019;14:e0226015. [PMID: 31830124 DOI: 10.1371/journal.pone.0226015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
18 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
19 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
20 Johnson CM, Linzay CD, Dassopoulos T. Maneuvering Clinical Pathways for Ulcerative Colitis. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0716-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Choi YI, Kim TJ, Park DK, Chung JW, Kim KO, Kwon KA, Kim YJ. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease. Int J Colorectal Dis. 2019;34:1713-1721. [PMID: 31471699 DOI: 10.1007/s00384-019-03368-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol 2020;18:1152-1160.e1. [PMID: 31419574 DOI: 10.1016/j.cgh.2019.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]